Altimmune (ALT) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CytomX Therapeutics (CTMX) has outperformed Altimmune (ALT) over the past year, losing 23.4% versus a loss of 32.3%. Over five years, CTMX leads with a -50.4% price change compared with -77.9% for ALT. CytomX Therapeutics is the larger company by market cap ($538.2 million vs $502.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | CTMX |
|---|---|---|
| Share price | $2.59 | $2.47 |
| Market cap | $502.83M | $538.21M |
| 1-day change | -2.82% | -3.14% |
| YTD return | -26.32% | -40.14% |
| 1-year return | -32.32% | -23.42% |
| 5-year return | -77.85% | -50.39% |
| EPS (TTM) | $-0.76 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $8.21 |
| 52-week low | $2.55 | $2.43 |
| Distance from 52-week high | -59.86% | -69.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +561.90% | +395.95% |
| Average volume | 4.18M | 3.34M |
| Shares outstanding | 194.52M | 217.90M |
| Employees | 57 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ALT vs CTMX FAQ
Which is bigger, Altimmune or CytomX Therapeutics?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $538.21M compared with $502.83M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or CTMX?
CTMX returned -23.42% over the past 12 months, compared with -32.32% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.